<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033213</url>
  </required_header>
  <id_info>
    <org_study_id>JORTK3</org_study_id>
    <nct_id>NCT02033213</nct_id>
  </id_info>
  <brief_title>Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial</brief_title>
  <official_title>Intraoperative Volume Restriction in Esophageal Carcinoma Surgery: an Exploratory Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinički Bolnički Centar Zagreb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinički Bolnički Centar Zagreb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory single-centre randomized clinical trial was performed in order to investigate
      whether the fluid volume administered during esophageal carcinoma surgery affects pulmonary
      gas exchange and tissue perfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A convenience sample of 16 patients admitted to the Department of Thoracic surgery University
      Hospital Centre Zagreb and scheduled for esophageal carcinoma surgery were enrolled
      prospectively in the study between June 2011 and August 2012.

      Patients were randomly allocated into two groups, one of which received ≤ 8ml/kg/h of
      intraoperative fluid (&quot;restrictive group&quot;) and another that received &gt; 8 ml/kg/h of fluid
      (&quot;liberal group&quot;).

      Patients were excluded if they were younger than 18 years; if they had severe lung disease,
      chronic renal insufficiency, or a physical status classification &gt; III on the American
      Society of Anesthesiologists (ASA) scale; or if it was impossible to perform epidural
      catheter placement or thoraco-phreno-laparotomy.

      All patients underwent esophagectomy carried out according to the Lewis-Tanner approach.

      Data on arterial oxygen partial pressure (PaO2), inspired oxygen fraction (FiO2), and the
      ratio PaO2/FiO2 were collected 10 min after anesthesia was induced and again 6 h after
      surgery. Data on the metabolic markers creatinine and lactate were collected 10 min after
      anesthesia induction and 6 h after surgery.

      ANOVA tests were performed to determine significant differences in mean values between study
      groups. Independent-sample t-tests were used to test differences in mean values between the
      restrictive and liberal groups for each of the two sets of measurements separately (10
      minutes after anesthesia induction and 6 hr after surgery). P &lt; 0.05 was considered
      significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Gas Exchange During and After Esophageal Carcinoma Surgery (PaO2/FiO2 Ratio)</measure>
    <time_frame>10 minutes, 6 hours</time_frame>
    <description>At the given time point, 10 minutes after beginning of the Lewis Tanner procedure and 6 hours after, arterial oxygen partial pressure (PaO2), inspired oxygen fraction (FiO2), and the PaO2/FiO2 ratio will be measured. The results of Pa02/FiO2 ratio will be compared between two groups for each time point separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine Values During and After Esophageal Carcinoma Surgery</measure>
    <time_frame>10 minutes, 6 hours</time_frame>
    <description>At the given time points, 10 minutes after beginning of the Lewis Tanner procedure and 6 hours after, creatinine blood levels will be measured. The results will be compared between two groups for each time point separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate Values During and After Esophageal Carcinoma Surgery</measure>
    <time_frame>10 minutes, 6 hours</time_frame>
    <description>At the given time points, ten minutes after beginning of the Lewis Tanner procedure and six hours after procedure, blood levels of the lactate will be measured and compared between two groups for each time point separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.</measure>
    <time_frame>10 minutes, 6 hours</time_frame>
    <description>At the given time points, ten minutes after beginning of the Lewis Tanner procedure and six hours after procedure, blood levels of the lactate will be measured and compared inside the same group (liberal or restrictive).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Surgery</measure>
    <time_frame>End of surgery.</time_frame>
    <description>Total time of Lewis-Tanner procedure will be measured and compared between two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Administered Intraoperative Fluid</measure>
    <time_frame>End of surgery</time_frame>
    <description>Total volume of intraoperatively given fluid according to the protocol will be measured and compared between two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Restrictive group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received &gt; 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restrictive group</intervention_name>
    <description>A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
    <arm_group_label>Restrictive group</arm_group_label>
    <other_name>Intraoperative restrictive fluid management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liberal group</intervention_name>
    <description>A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
    <arm_group_label>Liberal group</arm_group_label>
    <other_name>Intraoperative liberal fluid management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  esophageal carcinoma

          -  Lewis Tanner procedure (median laparotomy and right thoracotomy)

        Exclusion Criteria:

          -  younger than 18 years

          -  severe lung disease

          -  chronic renal insufficiency

          -  a physical status classification &gt; III on the American Society of Anesthesiologists
             (ASA) scale

          -  impossible to perform epidural catheter placement

          -  thoraco-phreno-laparotomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Karaman Ilić, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Centre Zagreb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Thoracic surgery &quot;Jordanovac&quot; University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <state>City of Zagreb</state>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <results_first_submitted>January 19, 2014</results_first_submitted>
  <results_first_submitted_qc>April 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2014</results_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinički Bolnički Centar Zagreb</investigator_affiliation>
    <investigator_full_name>Maja Karaman Ilić</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>intraoperative</keyword>
  <keyword>fluid management</keyword>
  <keyword>esophageal carcinoma</keyword>
  <keyword>surgery</keyword>
  <keyword>gas exchange</keyword>
  <keyword>tissue perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Restrictive Group</title>
          <description>Restrictive group: A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
        </group>
        <group group_id="P2">
          <title>Liberal Group</title>
          <description>Liberal group: A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Restrictive Group</title>
          <description>Restrictive group: A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
        </group>
        <group group_id="B2">
          <title>Liberal Group</title>
          <description>Liberal group: A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.91" spread="8.31"/>
                    <measurement group_id="B2" value="52.41" spread="13.41"/>
                    <measurement group_id="B3" value="53.12" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA score</title>
          <description>The American Society of Anesthesiologists (ASA) Physical Status classification system consists of six categories, as described below:
ASA PS 1: Normal healthy patient. ASA PS 2: Patients with mild systemic disease. ASA PS 3: Patients with severe systemic disease. ASA PS 4: Patients with severe systemic disease that is a constant threat to life. ASA PS 5: Moribund patients who are not expected to survive without the operation. ASA PS 6: A declared brain-dead patient who organs are being removed for donor purposes.
Smaller number is better.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.61" spread="0.51"/>
                    <measurement group_id="B2" value="2.75" spread="0.46"/>
                    <measurement group_id="B3" value="2.71" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.01" spread="18.91"/>
                    <measurement group_id="B2" value="66.31" spread="12.61"/>
                    <measurement group_id="B3" value="68.11" spread="17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Gas Exchange During and After Esophageal Carcinoma Surgery (PaO2/FiO2 Ratio)</title>
        <description>At the given time point, 10 minutes after beginning of the Lewis Tanner procedure and 6 hours after, arterial oxygen partial pressure (PaO2), inspired oxygen fraction (FiO2), and the PaO2/FiO2 ratio will be measured. The results of Pa02/FiO2 ratio will be compared between two groups for each time point separately.</description>
        <time_frame>10 minutes, 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrictive Group</title>
            <description>A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
          <group group_id="O2">
            <title>Liberal Group</title>
            <description>A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Gas Exchange During and After Esophageal Carcinoma Surgery (PaO2/FiO2 Ratio)</title>
          <description>At the given time point, 10 minutes after beginning of the Lewis Tanner procedure and 6 hours after, arterial oxygen partial pressure (PaO2), inspired oxygen fraction (FiO2), and the PaO2/FiO2 ratio will be measured. The results of Pa02/FiO2 ratio will be compared between two groups for each time point separately.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.01" spread="35.31"/>
                    <measurement group_id="O2" value="330.11" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.51" spread="32.91"/>
                    <measurement group_id="O2" value="307.11" spread="30.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The measurement was assessed at 10 minutes time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The measurement was assessed at 6 hours time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Creatinine Values During and After Esophageal Carcinoma Surgery</title>
        <description>At the given time points, 10 minutes after beginning of the Lewis Tanner procedure and 6 hours after, creatinine blood levels will be measured. The results will be compared between two groups for each time point separately.</description>
        <time_frame>10 minutes, 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrictive Group</title>
            <description>A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
          <group group_id="O2">
            <title>Liberal Group</title>
            <description>A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Values During and After Esophageal Carcinoma Surgery</title>
          <description>At the given time points, 10 minutes after beginning of the Lewis Tanner procedure and 6 hours after, creatinine blood levels will be measured. The results will be compared between two groups for each time point separately.</description>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.91" spread="12.67"/>
                    <measurement group_id="O2" value="90.88" spread="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.51" spread="16.37"/>
                    <measurement group_id="O2" value="100.88" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The measurement was assessed at 10 minutes time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.791</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The measurement was assessed at 6 hours time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lactate Values During and After Esophageal Carcinoma Surgery</title>
        <description>At the given time points, ten minutes after beginning of the Lewis Tanner procedure and six hours after procedure, blood levels of the lactate will be measured and compared between two groups for each time point separately.</description>
        <time_frame>10 minutes, 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrictive Group</title>
            <description>A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
          <group group_id="O2">
            <title>Liberal Group</title>
            <description>A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Lactate Values During and After Esophageal Carcinoma Surgery</title>
          <description>At the given time points, ten minutes after beginning of the Lewis Tanner procedure and six hours after procedure, blood levels of the lactate will be measured and compared between two groups for each time point separately.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.33"/>
                    <measurement group_id="O2" value="3.26" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="0.91"/>
                    <measurement group_id="O2" value="2.40" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The measurement aws assessed at 10 minutes time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.322</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The measurement was assessed at 6 hours time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.574</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.</title>
        <description>At the given time points, ten minutes after beginning of the Lewis Tanner procedure and six hours after procedure, blood levels of the lactate will be measured and compared inside the same group (liberal or restrictive).</description>
        <time_frame>10 minutes, 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrictive Group</title>
            <description>A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
          <group group_id="O2">
            <title>Liberal Group</title>
            <description>A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.</title>
          <description>At the given time points, ten minutes after beginning of the Lewis Tanner procedure and six hours after procedure, blood levels of the lactate will be measured and compared inside the same group (liberal or restrictive).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.33"/>
                    <measurement group_id="O2" value="3.26" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="0.91"/>
                    <measurement group_id="O2" value="2.40" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>P &lt; 0.05 was considered significant.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Surgery</title>
        <description>Total time of Lewis-Tanner procedure will be measured and compared between two groups.</description>
        <time_frame>End of surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrictive Group</title>
            <description>Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Restrictive group: A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
          <group group_id="O2">
            <title>Liberal Group</title>
            <description>Patients who received &gt; 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Liberal group: A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Surgery</title>
          <description>Total time of Lewis-Tanner procedure will be measured and compared between two groups.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.61" spread="91.21"/>
                    <measurement group_id="O2" value="324.41" spread="116.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of Administered Intraoperative Fluid</title>
        <description>Total volume of intraoperatively given fluid according to the protocol will be measured and compared between two groups.</description>
        <time_frame>End of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrictive Group</title>
            <description>Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Restrictive group: A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
          <group group_id="O2">
            <title>Liberal Group</title>
            <description>Patients who received &gt; 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Liberal group: A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Administered Intraoperative Fluid</title>
          <description>Total volume of intraoperatively given fluid according to the protocol will be measured and compared between two groups.</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2823.75" spread="965.8"/>
                    <measurement group_id="O2" value="3960.00" spread="755.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Restrictive Group</title>
          <description>A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
        </group>
        <group group_id="E2">
          <title>Liberal Group</title>
          <description>A group of patients who received &gt; 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of participants due to small overall number of patients with esophageal cancer treated in our hospital.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Maja Karaman Ilić, MD PhD</name_or_title>
      <organization>KBC Zagreb</organization>
      <phone>00385 1 2385 122</phone>
      <email>majakilic1@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

